---
title: "Interpretation of effectiveness between two interventions"
author: 'sumprain.netlify.com'
date: '2018-01-06'
slug: interpretation-of-effectivenes
categories:
  - bloglink
tags:
  - sumprainnetlifycom
---

[The investigators studied the effect of adding Daratumumab with Bortezomib, Melphalan and Prednisolone in patients with freshly detected Myeloma ineligible for Autologous Bone Marrow Transplantation. The primary outcome was Progression free survival (time to progression or death, whichever was early). The outcome was measured at 12 months and 18 months post initiation of<i class="fas fa-external-link-alt"></i>](https://sumprain.netlify.com/post/which_drug_better/)

